Booz Allen to Help FDA Modernize Human Drug Review Process

February 28, 2018

McLean, Va. – Driven by its responsibility to protect and promote public health, the U.S. Food and Drug Administration (FDA) ensures that patients and providers have timely and continued access to safe, effective, and high-quality medical products. To advance that mission, in October of 2017, the FDA’s Center for Drug Evaluation and Research (CDER) awarded Booz Allen Hamilton (NYSE: BAH) one of two spots on a competitive, $300 million Blanket Purchase Agreement (BPA) over seven years to support its implementation of a transformational Informatics Platform that will enable the Agency to bring life-saving drugs to market with greater speed and efficiency. 

“We are thrilled to partner with the FDA to deliver leading-edge informatics and analytics capabilities to expedite the approval of innovative new products and personalized medicines,” said Roman Salasznyk, Principal at Booz Allen. “Backed by our team of experienced data scientists and technologists, we will work with CDER to provide its reviewer community an integrated Platform that will enable the rapid processing, validation, management, and analysis of data across the medical product lifecycle. Holistic drug review management is the future, and we look forward to helping the FDA continue its exceptional mission performance on behalf of the American public.”    

Read more about Booz Allen’s commitment to helping healthcare and life sciences organizations across the private and public sectors, here: www.boozallen.com/markets/health.html.